Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Dividend Safety Check: SNPD and a Portfolio of Dividend Stalwarts
10:00am, Thursday, 11'th Jun 2026
If you own SNPD (NYSEARCA:SNPD) for the income, the question worth answering is whether the distribution stream is built on companies that can keep paying through a recession or whether it leans on yi
Johnson & Johnson Eyes Rare Disease Expansion
09:58am, Thursday, 11'th Jun 2026
Johnson and Johnson (JNJ) is making a stronger case for expanding Imaavy into a rare autoimmune blood disorder after posting detailed Phase 2/3 data from its ENER
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
08:00am, Thursday, 11'th Jun 2026
Johnson and Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IO
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
07:45am, Thursday, 11'th Jun 2026
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell
05:57am, Thursday, 11'th Jun 2026
A retired couple with a $2 million dividend-focused portfolio yielding roughly 6%, or $120,000 per year, watched their income stream fall by $14,400 during a difficult market period as covered-call fu
Patients in the IMAAVY 30 mg/kg treatment group a achieved statistically significant durable hemoglobin response b , with mean hemoglobin improvement of at least 1 g/dL as early as Week 1 c More pa
I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow
12:39pm, Wednesday, 10'th Jun 2026
I keep buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a fire took my brokerage statement to zero tomorrow, those are the three tickers I would start typing in again on day one.
The Portfolio That Gets You a Waterfront Condo in Miami Beach
11:24am, Wednesday, 10'th Jun 2026
Ten thousand dollars a month in dividend income works out to $120,000 per year. That is enough to cover the rent on a luxury waterfront condo in Miami Beach, one of the most expensive rental markets i
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
11:22am, Wednesday, 10'th Jun 2026
LOS ANGELES--(BUSINESS WIRE)-- #JohnsonJohnson--A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma after years of exposure to an asbestos
Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond
11:20am, Wednesday, 10'th Jun 2026
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a rare long-duration compounder because it is the rare equity whose credit quality, dividend record, and demand profile collectively rival a sove
Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
06:20am, Wednesday, 10'th Jun 2026
Joaquin Duato said finding a cure for certain cancers and turning others into chronic diseases is an achievable target for the coming decade.
Johnson & Johnson (JNJ) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
04:12pm, Tuesday, 09'th Jun 2026
Johnson & Johnson (JNJ) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
12:20pm, Tuesday, 09'th Jun 2026
JNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
12:06pm, Tuesday, 09'th Jun 2026
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
